Please Wait.....
Report
Cell & Gene Therapy Clinical Trial Services Market - By Service (Clinical Trial Design & Planning), Phase, Indication, Therapy Type (Gene, Cell, Gene Modified Cell Therapy), End-use (Pharmaceutical & Biotechnology, CRO) - Global Forecast (2024 ? 2032)
Market Report I 2024-05-06 I 209 Pages I Global Market Insights
Global Cell & Gene Therapy Clinical Trial Services Market size will expand at a 10.8 CAGR from 2024 to 2032, attributed to technological upgrades, such as CRISPR-Cas9 and viral vectors, in line with supportive regulatory environments. These innovations enhance therapeutic potential and streamline approval processes, stimulating increased research and trial activities. With regulatory agencies like the FDA facilitating faster approvals for groundbreaking therapies, there is a growing momentum among biotech firms and pharmaceutical companies to invest in and accelerate the development of novel treatments, fueling market growth.
For instance, in June 2023, the FDA launched a new office to handle a surge in cell and gene therapy submissions, including potential approvals for the first CRISPR therapy and gene therapy for Duchenne muscular dystrophy. This development signifies heightened regulatory activity and industry momentum, stimulating growth opportunities for service providers supporting these trials, ranging from patient recruitment to regulatory compliance and data management.
The cell amp gene therapy clinical trial services industry is fragmented based on service, phase, indication, therapy type, end-use, and region.
The neurology segment will garner remarkable gains through 2032, spurred by the pressing need for effective treatments for neurological disorders. With conditions like Parkinson's, Alzheimer's, and ALS driving research, there is a substantial investment in therapies targeting these areas. Clinical trials in neurology benefit from specialized expertise, robust patient recruitment networks, and regulatory support, making it a focal point for innovation. Advances in gene editing and cell therapies offer promising avenues for addressing unmet medical needs, further bolstering this segment's prominence.
The academic and research institutions segment will see a considerable surge by 2032, owing to their pivotal role in pioneering innovative therapies and conducting early-stage trials. These institutions possess extensive expertise, infrastructure, and access to patient populations critical for advancing research. Collaborations with biotech firms and government funding bolster their capabilities. As demand grows for cutting-edge therapies, academic and research institutions will conduct essential clinical trials that validate the safety and efficacy of cell and gene therapies.
Asia Pacific cell amp gene therapy clinical trial services market share will experience a notable CAGR between 2024 and 2032 due to increasing investments in healthcare infrastructure, rising prevalence of genetic disorders, and supportive regulatory environments. The region's diverse patient population and lower operational costs attract global biotech and pharmaceutical firms to conduct clinical trials. As countries like China, Japan, and South Korea advance in biotechnology and genetic research, Asia Pacific will stand as a key contributor to the expansion of the global cell amp gene therapy clinical trial services industry.
Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of chronic and genetic disease
3.2.1.2 Technological advancement in cell and gene therapy
3.2.1.3 Increasing investment in research & development activities
3.2.1.4 Expanded application in oncology and rare disease
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory challenges
3.2.2.2 High development cost
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Service, 2021-2032 ($ Million)
5.1 Key trends
5.2 Clinical trial design & planning
5.3 Supply & logistics services
5.4 Regulatory affairs & compliance
5.5 Data management & biostatistics
5.6 Site management & monitoring
5.7 Other services
Chapter 6 Market Estimates and Forecast, By Phase, 2021-2032 ($ Million)
6.1 Key trends
6.2 Phase I
6.3 Phase II
6.4 Phase III
6.5 Phase IV
Chapter 7 Market Estimates and Forecast, By Indication, 2021-2032 ($ Million)
7.1 Key trends
7.2 Oncology
7.3 Hematology
7.4 Endocrine/metabolic disorders
7.5 Infectious diseases
7.6 Neurology
7.7 Cardiovascular diseases
7.8 Musculoskeletal disorders
7.9 Other indications
Chapter 8 Market Estimates and Forecast, By Therapy Type, 2021-2032 ($ Million)
8.1 Key trends
8.2 Gene therapy
8.3 Cell therapy
8.4 Gene modified cell therapy
Chapter 9 Market Estimates and Forecast, By End-Use, 2021-2032 ($ Million)
9.1 Key trends
9.2 Pharmaceutical & biotechnology companies
9.3 Contract research organizations
9.4 Academic & research institutes
9.5 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021-2032 ($ Million)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 ADVARRA
11.2 Charles River Laboratories International Inc.
11.3 Catalent Pharma
11.4 ICON PLC
11.5 IQVIA
11.6 Medpace, Inc.
11.7 Novotech
11.8 Precision Medicine Group, LLC
11.9 Parexel International
11.10 Syneos Health
11.11 Sharp Services, LLC
11.12 Thermo Fisher Scientific Inc.
11.13 Worldwide Clinical Trials
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security